ESMO及《新英格蘭醫學雜誌》同步發佈OptiTROP-Lung06研究結果!蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗顯著延長PFS
PFS顯著延長:經BICR評估,疾病進展或死亡風險降低51% (HR 0.49;95% CI 0.36-0.65;P
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


